Scientists Discover Why Some Cancers May Not Respond to Immunotherapy
February 9, 2017
Rheumatoid arthritis and skin problems: Causes and treatment
February 9, 2017
Show all

Publication of ocrelizumab trials: hope for progressive MS

The medication ocrelizumab is the first treatment to show it can slow disability progression for people with primary progressive MS.

Ocrelizumab can slow progression of MS. This is according to the newly published results of its phase 3 trials.

It is the first treatment that can slow the advancement of primary progressive MS. It can also treat relapsing MS.

The full results of three final stage clinical trials were published in the New England Journal of Medicine today.

Treating primary progressive MS

In a phase 3 trial, ocrelizumab reduced the MS progression by 25% in people with primary progressive MS. This was compared with a placebo over the course of two years.

Scientists focused on symptoms defined in the Expanded Disability Status Scale. These include problems with walking, thinking and swallowing.

The team also found that treatment with ocrelizumab decreased the total volume of brain lesions seen on MRI, whereas lesion volume increased in those treated with placebo.

Read full article: Publication of ocrelizumab trials: hope for progressive MS | Multiple Sclerosis Society UK

Read Full Article: Publication of ocrelizumab trials: hope for progressive MS | Multiple Sclerosis Society UK

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.